(AVIR) Atea Pharmaceuticals - Overview
Stock: Antiviral, Oral, Hepatitis, Clinical, Regimen
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 49.7% |
| Relative Tail Risk | -9.20% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.78 |
| Alpha | 21.46 |
| Character TTM | |
|---|---|
| Beta | 0.645 |
| Beta Downside | 0.552 |
| Drawdowns 3y | |
|---|---|
| Max DD | 49.60% |
| CAGR/Max DD | -0.01 |
Description: AVIR Atea Pharmaceuticals December 31, 2025
Atea Pharmaceuticals (NASDAQ:AVIR) is a Boston-based, clinical-stage biotech that focuses on oral antivirals for serious viral infections. The company was founded in 2012 and trades as a common stock under the U.S. GICS sub-industry “Pharmaceuticals.”
The flagship regimen combines bemnifosbuvir (an NS5B polymerase inhibitor) with ruzasvir (an NS5A inhibitor) and is currently in a Phase 3 trial for hepatitis C virus (HCV). Atea holds a development, manufacturing, and commercialization license for ruzasvir from MSD International GmbH, which could accelerate market entry if the trial meets its primary endpoints.
Key market and financial context: the global HCV therapeutic market is estimated at roughly $10 billion, but is contracting as cure rates improve and screening expands; the average cash runway for small-cap biotech firms in 2024 is about 12 months, and Atea reported approximately $45 million in cash and short-term investments in its latest filing, implying a near-term need for either partner funding or trial-related milestones. Additionally, the broader antiviral sector is experiencing a 7-8% YoY increase in R&D spend, driven by heightened investor interest in pandemic-preparedness pipelines.
If you want a data-driven snapshot of AVIR’s valuation metrics and how they compare to sector peers, a quick look at ValueRay’s analyst toolkit can help you gauge the risk-adjusted upside.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -147.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.39 > 0.02 and ΔFCF/TA -13.28 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.39 > 3% & CFO -134.2m > Net Income -147.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 16.66 > 1.5 & < 3 |
| Outstanding Shares: last quarter (79.1m) vs 12m ago -6.36% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.10% > 50% (prev 0.0%; Δ 0.10% > 0%) |
| Interest Coverage Ratio: -16.49 > 6 (EBITDA TTM -155.2m / Interest Expense TTM -9.44m) |
Altman Z'' -15.00
| A: 0.92 (Total Current Assets 336.1m - Total Current Liabilities 20.2m) / Total Assets 343.0m |
| B: -1.39 (Retained Earnings -477.7m / Total Assets 343.0m) |
| C: -0.37 (EBIT TTM -155.6m / Avg Total Assets 417.0m) |
| D: -17.56 (Book Value of Equity -477.4m / Total Liabilities 27.2m) |
| Altman-Z'' Score: -19.45 = D |
What is the price of AVIR shares?
Over the past week, the price has changed by -2.12%, over one month by +21.70%, over three months by +27.69% and over the past year by +33.87%.
Is AVIR a buy, sell or hold?
- StrongBuy: 1
- Buy: 0
- Hold: 1
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the AVIR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 7.7 | 84.8% |
| Analysts Target Price | 7.7 | 84.8% |
| ValueRay Target Price | 4.7 | 12.5% |
AVIR Fundamental Data Overview February 03, 2026
P/B = 1.049
Revenue TTM = 416.0k USD
EBIT TTM = -155.6m USD
EBITDA TTM = -155.2m USD
Long Term Debt = 1.04m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 832.0k USD (from shortTermDebt, last quarter)
Debt = 1.04m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -76.3m USD (from netDebt column, last quarter)
Enterprise Value = 2.99m USD (331.3m + Debt 1.04m - CCE 329.3m)
Interest Coverage Ratio = -16.49 (Ebit TTM -155.6m / Interest Expense TTM -9.44m)
EV/FCF = -0.02x (Enterprise Value 2.99m / FCF TTM -134.2m)
FCF Yield = -4483 % (FCF TTM -134.2m / Enterprise Value 2.99m)
FCF Margin = -32.3k% (FCF TTM -134.2m / Revenue TTM 416.0k)
Net Margin = -35.3k% (Net Income TTM -147.0m / Revenue TTM 416.0k)
Gross Margin = -1333 % ((Revenue TTM 416.0k - Cost of Revenue TTM 5.96m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 0.01 (Enterprise Value 2.99m / Total Assets 343.0m)
Interest Expense / Debt = 612.7% (Interest Expense 6.40m / Debt 1.04m)
Taxrate = 21.0% (US default 21%)
NOPAT = -123.0m (EBIT -155.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 16.66 (Total Current Assets 336.1m / Total Current Liabilities 20.2m)
Debt / Equity = 0.00 (Debt 1.04m / totalStockholderEquity, last quarter 315.8m)
Debt / EBITDA = 0.49 (negative EBITDA) (Net Debt -76.3m / EBITDA -155.2m)
Debt / FCF = 0.57 (negative FCF - burning cash) (Net Debt -76.3m / FCF TTM -134.2m)
Total Stockholder Equity = 382.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -35.26% (Net Income -147.0m / Total Assets 343.0m)
RoE = -38.43% (Net Income TTM -147.0m / Total Stockholder Equity 382.5m)
RoCE = -40.57% (EBIT -155.6m / Capital Employed (Equity 382.5m + L.T.Debt 1.04m))
RoIC = -32.14% (negative operating profit) (NOPAT -123.0m / Invested Capital 382.5m)
WACC = 8.26% (E(331.3m)/V(332.3m) * Re(8.29%) + (debt cost/tax rate unavailable))
Discount Rate = 8.29% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -2.66%
Fair Price DCF = unknown (Cash Flow -134.2m)
EPS Correlation: -48.11 | EPS CAGR: -42.83% | SUE: -0.82 | # QB: 0
Revenue Correlation: -40.38 | Revenue CAGR: -47.24% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.53 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=1
EPS next Year (2026-12-31): EPS=-1.75 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=-1.2% | Growth Revenue=+0.0%